Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, urine-derived biochemical products, nifedipine controlled release tablets, azithromycin, ceftriaxone sodium for injection, methylprednisolone sodium succinate for injection, cefuroxime tablets/capsules, ampicillin acid, penicillin industrial potassium salt, Touboke Yuekui granules/capsules, remifentanil hydrochloride for injection, sodium cefuroxime for injection, ceftriaxone sodium crude salt, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, 7-ACA, amlodipine besylate tablets, cefoperazone dispersible tablets, and amoxicillin capsules. Shanghai Shyndec Pharmaceutical Co., Ltd. was founded in 2000 and is headquartered in Shanghai, China.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Liu, Yong

Employees

11,472

Website

www.shyndec.com

IPO Date

2004-06-16

Headquarters

No. 378, Jianlu Road, Pudong New Area, Shanghai 200137, China

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.